Ramipril Capsule
Product Images NDC 51655-975

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-975-52 (51655 975 52 Rev A 02 23)

Label for Ramipril Capsules, USP 2.5 mg, containing 30 capsules. It is a prescription-only oral capsule product labeled by Northwind Health Company, LLC. The label includes storage instructions, dosage directions, and packaging details with relevant barcodes and product identification numbers.*

FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

A line graph comparing the proportion of patients over days of follow-up between Ramipril and placebo groups. The x-axis represents days of follow-up up to about 1500, and the y-axis shows the proportion of patients ranging from 0 to 0.20. The graph includes a P value of 0.0001 indicating statistical comparison. Ramipril's line is solid and lies below the dashed line for placebo, showing a lower proportion of patients over time on Ramipril.*

FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

A forest plot chart illustrating the relative risk of a composite clinical outcome in patients treated with Ramipril compared to placebo. The chart lists various patient subgroups, including cardiovascular disease status, diabetes, age, sex, hypertension, coronary artery disease history, prior myocardial infarction, cerebrovascular and peripheral vascular diseases, and presence of microalbuminuria. Each subgroup shows the number of patients, incidence in the placebo group, and relative risk with 95% confidence intervals depicted as horizontal lines and squares on a logarithmic scale.*

FDA Label Image

Chemical Structure (Ramipril Str)

Chemical structure of the active ingredient Ramipril, showing its molecular framework with rings and functional groups typical for this ACE inhibitor medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.